Embla Medical hf: Interim Report Q3 2025
Announcement no. 49/2025 Interim report Q3 2025 21 October 2025 Sveinn Sölvason, President and CEO, comments: “Sales in Q3 2025 amounted to USD 237 million, representing 11% reported growth, of which 7% was organic. Growth picked up in the third quarter as expected, driven by double-digit growth in Prosthetics & Neuro Orthotics. The solid momentum […]